RxDoctor Payments DataLook up a doctor →

Spero Cataland, MD

Hematology · Columbus, OHNPI 1881602209

Payments from drug & device makers

$2,835,960in general payments, 2019–2025

Across 793 payments — averaging $3576.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$1.7M
  • AstraZeneca$402K
  • Sanofi$243K
  • Argenx US, Inc.$215K
  • Genentech, Inc.$135K
  • Bioverativ Therapeutics Inc.$20K
  • plus $80K from 9 others
$16,389in research payments, 2019–2025

Across 27 payments — averaging $606.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$11K
  • AstraZeneca$4K
  • Bioverativ Therapeutics Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,835,960 in reported general payments places this provider in the 85th percentile of 84 hematology providers in Ohio.

See all hematology providers in Ohio

Medicare billing

Part B allowed, 2024
$16,555
Medicare patients
158
Services billed
195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →